文献速递类风湿关节炎

血清阳性类风湿关节炎新发心房颤动:与改善病情抗风湿药治疗的关联

New-onset atrial fibrillation in seropositive rheumatoid arthritis: association with disease-modifying anti-rheumatic drugs treatment.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于韩国健康保险审查评价院数据库2010至2020年新诊断血清阳性类风湿关节炎患者,采用巢式病例对照分析按年龄、性别、随访时长和诊断指数年1:4匹配,发现甲氨蝶呤降低新发心房颤动风险(aOR 0.89),来氟米特增加风险(aOR 1.21),且风险模式随年龄和性别不同。

要点

  • 甲氨蝶呤使用与新发心房颤动风险降低相关(aOR 0.89)。
  • 来氟米特使用与新发心房颤动风险升高相关(aOR 1.21)。
  • ≥50岁患者中来氟米特和阿达木单抗增加心房颤动发生,男性中甲氨蝶呤降低风险,女性中来氟米特增加风险。

核心结论

  • 尽管新发心房颤动的受试者数量较少,甲氨蝶呤降低而来氟米特增加类风湿关节炎患者的新发心房颤动。
  • 尤其观察到改善病情抗风湿药使用相关的心房颤动风险模式随年龄和性别不同。

研究设计与样本

  • 使用韩国健康保险审查评价院数据库识别2010至2020年间新诊断的血清阳性类风湿关节炎患者。
  • 采用巢式病例对照分析,按年龄、性别、随访时长和血清阳性类风湿关节炎诊断指数年以1:4比例将发生心房颤动的患者与未发生对照匹配。
  • 使用调整条件逻辑回归识别心房颤动的预测因素。

主要发现

  • 108 085例血清阳性类风湿关节炎患者中,2 629例(2.4%)发生新发心房颤动,女性比例约67%。
  • 在匹配人群中,既存高血压、慢性肾脏病和心力衰竭合并症与心房颤动风险增加相关。
  • 甲氨蝶呤使用降低新发心房颤动风险(aOR 0.89),来氟米特使用增加心房颤动(aOR 1.21)。
  • 在≥50岁患者亚组中,来氟米特和阿达木单抗增加心房颤动发生,甲氨蝶呤在男性中降低心房颤动,来氟米特在女性中增加该风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Atrial fibrillation (AF) is a potentially lethal complication that leads to increased hospitalization, disability and mortality. Furthermore, the risk of cardiovascular disease is increased in RA. We evaluated whether DMARD treatment is associated with incident AF in patients with seropositive RA (SPRA). METHODS: The South Korean Health Insurance Review and Assessment Service database was used to identify patients newly diagnosed with SPRA between 2010 and 2020. A nested case-control analysis was performed to match AF-affected patients to unaffected controls for age, sex, follow-up duration, and index year of SPRA diagnosis at a 1:4 ratio. Adjusted conditional logistic regression was used to identify the predictive factors for AF. RESULTS: Of the 108 085 patients with SPRA, 2,629 (2.4%) developed new-onset AF, and the proportion of females was ∼67%. In the matched population, pre-existing comorbidities of hypertension, chronic kidney disease, and heart failure were associated with increased risk of AF. Meanwhile, the use of methotrexate (MTX) decreased the risk of incident AF [adjusted odds ratio (aOR), 0.89], whereas the use of leflunomide (LEF) increased AF (aOR, 1.21). In a subgroup of patients aged ≥50 years, LEF and adalimumab increased the occurrence of AF, while MTX decreased AF in males and LEF increased this risk in females. CONCLUSION: Although the number of subjects developing new-onset AF was small, MTX decreased and LEF increased incident AF in patients with RA. Especially, a distinct pattern of AF risk with DMARDs usage was observed according to age and sex.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kim HW, Han M, Jung I, et al. New-onset atrial fibrillation in seropositive rheumatoid arthritis: association with disease-modifying anti-rheumatic drugs treatment. Rheumatology (Oxford). 2024. PMID: 37421392. doi:10.1093/rheumatology/kead336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。